Last reviewed 2026-04-19 · How we verify

valethamate

unknown active

valethamate is a drug. It is currently in unknown development.

At a glance

Generic name	valethamate
Target	Cytochrome P450 2D6, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2
Therapeutic area	Other
Phase	unknown

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida: A Randomised Controlled Trial. (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

valethamate CI brief — competitive landscape report
valethamate updates RSS · CI watch RSS
portfolio CI

Frequently asked questions about valethamate

What is valethamate?

valethamate is a pharmaceutical drug.

What development phase is valethamate in?

valethamate is in unknown.

What does valethamate target?

valethamate targets Cytochrome P450 2D6, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2.

Target: All drugs targeting Cytochrome P450 2D6, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2
Manufacturer: — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing